217 related articles for article (PubMed ID: 17567730)
1. Role of small intestinal cytochromes p450 in the bioavailability of oral nifedipine.
Zhang QY; Kaminsky LS; Dunbar D; Zhang J; Ding X
Drug Metab Dispos; 2007 Sep; 35(9):1617-23. PubMed ID: 17567730
[TBL] [Abstract][Full Text] [Related]
2. An intestinal epithelium-specific cytochrome P450 (P450) reductase-knockout mouse model: direct evidence for a role of intestinal p450s in first-pass clearance of oral nifedipine.
Zhang QY; Fang C; Zhang J; Dunbar D; Kaminsky L; Ding X
Drug Metab Dispos; 2009 Mar; 37(3):651-7. PubMed ID: 19056912
[TBL] [Abstract][Full Text] [Related]
3. Transgenic mice with a hypomorphic NADPH-cytochrome P450 reductase gene: effects on development, reproduction, and microsomal cytochrome P450.
Wu L; Gu J; Cui H; Zhang QY; Behr M; Fang C; Weng Y; Kluetzman K; Swiatek PJ; Yang W; Kaminsky L; Ding X
J Pharmacol Exp Ther; 2005 Jan; 312(1):35-43. PubMed ID: 15328377
[TBL] [Abstract][Full Text] [Related]
4. Effects of 5-fluorouracil on the drug-metabolizing enzymes of the small intestine and the consequent drug interaction with nifedipine in rats.
Yoshisue K; Nagayama S; Shindo T; Kawaguchi Y
J Pharmacol Exp Ther; 2001 Jun; 297(3):1166-75. PubMed ID: 11356943
[TBL] [Abstract][Full Text] [Related]
5. A mouse model with liver-specific deletion and global suppression of the NADPH-cytochrome P450 reductase gene: characterization and utility for in vivo studies of cyclophosphamide disposition.
Gu J; Chen CS; Wei Y; Fang C; Xie F; Kannan K; Yang W; Waxman DJ; Ding X
J Pharmacol Exp Ther; 2007 Apr; 321(1):9-17. PubMed ID: 17218484
[TBL] [Abstract][Full Text] [Related]
6. Role of hepatic cytochrome p450s in the pharmacokinetics and toxicity of cyclophosphamide: studies with the hepatic cytochrome p450 reductase null mouse.
Pass GJ; Carrie D; Boylan M; Lorimore S; Wright E; Houston B; Henderson CJ; Wolf CR
Cancer Res; 2005 May; 65(10):4211-7. PubMed ID: 15899812
[TBL] [Abstract][Full Text] [Related]
7. Metabolic activation of benzo[a]pyrene in vitro by hepatic cytochrome P450 contrasts with detoxification in vivo: experiments with hepatic cytochrome P450 reductase null mice.
Arlt VM; Stiborová M; Henderson CJ; Thiemann M; Frei E; Aimová D; Singh R; Gamboa da Costa G; Schmitz OJ; Farmer PB; Wolf CR; Phillips DH
Carcinogenesis; 2008 Mar; 29(3):656-65. PubMed ID: 18204078
[TBL] [Abstract][Full Text] [Related]
8. Regulation of intestinal cytochrome P450 expression by hepatic cytochrome P450: possible involvement of fibroblast growth factor 15 and impact on systemic drug exposure.
Zhu Y; Ding X; Fang C; Zhang QY
Mol Pharmacol; 2014 Jan; 85(1):139-47. PubMed ID: 24184963
[TBL] [Abstract][Full Text] [Related]
9. Effects of liver fibrosis on verapamil pharmacokinetics in rats.
Chen M; Xu D; Hu XL; Wang H
Clin Exp Pharmacol Physiol; 2008 Mar; 35(3):287-94. PubMed ID: 17973928
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of mebudipine, a new calcium antagonist, following single intravenous and oral administrations in rats.
Bohlooli S; Keyhanfar F; Mahmoudian M
Biopharm Drug Dispos; 2004 May; 25(4):187-91. PubMed ID: 15108221
[TBL] [Abstract][Full Text] [Related]
11. Effects of long-term grapefruit juice ingestion on nifedipine pharmacokinetics: induction of rat hepatic P-450 by grapefruit juice.
Mohri K; Uesawa Y; Sagawa Ki
Drug Metab Dispos; 2000 Apr; 28(4):482-6. PubMed ID: 10725318
[TBL] [Abstract][Full Text] [Related]
12. The role of small-intestinal P450 enzymes in protection against systemic exposure of orally administered benzo[a]pyrene.
Fang C; Zhang QY
J Pharmacol Exp Ther; 2010 Jul; 334(1):156-63. PubMed ID: 20400470
[TBL] [Abstract][Full Text] [Related]
13. Conditional knockout of the mouse NADPH-cytochrome p450 reductase gene.
Wu L; Gu J; Weng Y; Kluetzman K; Swiatek P; Behr M; Zhang QY; Zhuo X; Xie Q; Ding X
Genesis; 2003 Aug; 36(4):177-81. PubMed ID: 12929087
[TBL] [Abstract][Full Text] [Related]
14. Effect of cyclosporine on drug transport and pharmacokinetics of nifedipine.
Dorababu M; Nishimura A; Prabha T; Naruhashi K; Sugioka N; Takada K; Shibata N
Biomed Pharmacother; 2009 Nov; 63(9):697-702. PubMed ID: 19819100
[TBL] [Abstract][Full Text] [Related]
15. The nifedipine-rifampin interaction. Evidence for induction of gut wall metabolism.
Holtbecker N; Fromm MF; Kroemer HK; Ohnhaus EE; Heidemann H
Drug Metab Dispos; 1996 Oct; 24(10):1121-3. PubMed ID: 8894514
[TBL] [Abstract][Full Text] [Related]
16. Cytochrome P450-mediated metabolism in the human gut wall.
Thelen K; Dressman JB
J Pharm Pharmacol; 2009 May; 61(5):541-58. PubMed ID: 19405992
[TBL] [Abstract][Full Text] [Related]
17. Development of coated nifedipine dry elixir as a long acting oral delivery with bioavailability enhancement.
Choi JY; Jin SE; Park Y; Lee HJ; Park Y; Maeng HJ; Kim CK
Arch Pharm Res; 2011 Oct; 34(10):1711-7. PubMed ID: 22076771
[TBL] [Abstract][Full Text] [Related]
18. Lack of drug-drug interaction between cerivastatin and nifedipine.
Sachse R; Brendel E; Mück W; Rohde G; Ochmann K; Horstmann R; Kuhlmann J
Int J Clin Pharmacol Ther; 1998 Aug; 36(8):409-13. PubMed ID: 9726692
[TBL] [Abstract][Full Text] [Related]
19. Inhibitory effect of docosahexaenoic acid (DHA) on the intestinal metabolism of midazolam: in vitro and in vivo studies in rats.
Hirunpanich V; Murakoso K; Sato H
Int J Pharm; 2008 Mar; 351(1-2):133-43. PubMed ID: 18082981
[TBL] [Abstract][Full Text] [Related]
20. Stereoselective first-pass metabolism of verapamil in the small intestine and liver in rats.
Hanada K; Ikemi Y; Kukita K; Mihara K; Ogata H
Drug Metab Dispos; 2008 Oct; 36(10):2037-42. PubMed ID: 18617604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
